Kim Simonsen has been appointed chief development officer at Anergis SA in Switzerland to lead the company’s global product development activities. Anergis’ lead product is an immunotherapy for birch pollen allergy which is poised to enter Phase 3 development.
Dr Simonsen joins Anergis from Ablynx NV where he was chief operations officer. Prior to that, he was senior director of global clinical development at ALK Abello A/S where he led development of the first marketed grass pollen allergy immunotherapy tablet. Dr Simonsen has also held clinical development positions at Novartis and Novo Nordisk A/S.
The executive trained as a medical doctor at Copenhagen University in Denmark.
Anergis announced the appointment on 2 June 2015.
Copyright 2015 Evernow Publishing Ltd